Literature DB >> 10930094

Immunotherapy of a murine T cell lymphoma localized to the brain.

V K Ghant1, N S Hiramoto, G Y Gillespie, D K Gauthier, R N Hiramoto.   

Abstract

Mouse YC8 T cell lymphoma was used as a model to determine whether an effective immunotherapy procedure could be devised for the treatment of lymphoma localized to the brain. Implantation of 5 x 10(4) YC8 cells into the left cerebral hemisphere induced rapid loss of the animal's body weight. Severe loss of weight and early deaths were observed in the untreated control group. Although resistance can be conferred to the brain by immunization of naive BALB/c mice, adoptive chemoimmunotherapy procedures were surprisingly not effective in inducing remissions in animals with lymphoma confined to the brain. Even passive transfer of effector cells from immunized, tumor resistant donor animals combined with systemic IL-2 treatment did not impart resistance to recipients with brain tumors. However, regression of the intracranial tumor and apparent cures could be accomplished, when ex vivo cultured effector cells were transferred intravenously.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930094     DOI: 10.1023/a:1006475516746

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Conditioning: a new approach to immunotherapy.

Authors:  V K Ghanta; N S Hiramoto; H B Solvason; S J Soong; R N Hiramoto
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

2.  Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.

Authors:  M Awwad; R J North
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

3.  Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group.

Authors:  T R Coté; A Manns; C R Hardy; F J Yellin; P Hartge
Journal:  J Natl Cancer Inst       Date:  1996-05-15       Impact factor: 13.506

4.  Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.

Authors:  M Ogasawara; S A Rosenberg
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

5.  Role of immune cells in the Pavlovian conditioning of specific resistance to cancer.

Authors:  R N Hiramoto; N S Hiramoto; M E Rish; S J Soong; D M Miller; V K Ghanta
Journal:  Int J Neurosci       Date:  1991-07       Impact factor: 2.292

Review 6.  Primary central nervous system lymphoma.

Authors:  J W Grant; P G Isaacson
Journal:  Brain Pathol       Date:  1992-04       Impact factor: 6.508

7.  In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.

Authors:  N Takai; R Tanaka; S Yoshida; N Hara; T Saito
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

8.  Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; W M Linehan; C Seipp; S Calabro; S E Karp; R M Sherry; S Steinberg; D E White
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

9.  Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice.

Authors:  M Saito; M Nanjo; M Kataoka; Y Moriya; Y Sugawara; T Yoshida; N Ishida
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

10.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

Authors:  P D Greenberg; D E Kern; M A Cheever
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.

Authors:  Rym Ben Abdelwahed Bagga; Sabrina Donnou; Jérémie Cosette; Catherine Sautès-Fridman; Mahjoub Aouni; Sylvain Fisson
Journal:  J Neurooncol       Date:  2014-10-10       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.